ENTX - Entera Bio Ltd logo

ENTX

Entera Bio Ltd

Entera Bio Ltd develops oral peptide and protein replacement therapies, focusing on osteoporosis and related conditions. Its candidates include EB613 for osteoporosis and EB612 for hypoparathyroidism, utilizing the N-Tabβ„’ oral delivery platform.

βš•οΈ Healthcare NASDAQ Listed 2018 $ USD
$1,000 invested 5 years ago β†’$506today

Score Overview

1 Year
Score
Net Growth53.08%
Net TrendGrew
Net Income Consistencyβ€”
Rev Growth-100.00%
Rev TrendShrank
Revenue Consistencyβ€”
5 Years
Score3.7
Net Growth55.96%
Net Trend40%
Net Income Consistencyβ€”
Rev Growth-100.00%
Rev Trend20%
Revenue Consistencyβ€”
All Time
Score
Net Growth47.91%
Net Trend38%
Net Income Consistency
Rev Growth-100.00%
Rev Trend38%
Revenue Consistency

See the full market ranking β†’

Entera Bio Ltd fundamental performance

Between 2020 and 2025, revenue declined from $ 365K to $ 42K and net income went from -$ 9M to -$ 11M. Revenue increased in 1 of those 5 years; net income in 2.

Entera Bio Ltd currently holds a 5-year HDB Score of 3.7 out of 10. How the HDB Score is calculated.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 2.80β€”
1 Year2025-08-12
$ 1.8948.15%
5 Years2021-08-12
$ 5.53-49.37%
All Time2018-06-28
$ 6.28-55.41%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 0.00-$ 5M$ 4M
2025$ 42K-$ 11M$ 7M
2024$ 181K-$ 9M$ 8M
2023$ 14K-$ 8M$ 11M
2022$ 134K-$ 13M$ 12M
2021$ 571K-$ 12M$ 24M
2020$ 365K-$ 9M$ 8M
2019$ 236K-$ 10M$ 15M
IPO2018$ 500K-$ 10M$ 11M

Explore beyond ENTX

You're looking at Entera Bio Ltd. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies